Cantor Fitzgerald set a $13.00 target price on Viewray (NASDAQ:VRAY) in a research report sent to investors on Monday, January 8th. The firm currently has a buy rating on the stock. Cantor Fitzgerald also issued estimates for Viewray’s FY2017 earnings at ($1.03) EPS and FY2018 earnings at ($0.59) EPS.
VRAY has been the subject of a number of other research reports. ValuEngine lowered shares of Viewray from a hold rating to a sell rating in a report on Friday, September 22nd. Mizuho reissued a buy rating and issued a $12.00 price objective on shares of Viewray in a report on Wednesday, October 25th. BidaskClub raised shares of Viewray from a hold rating to a buy rating in a report on Friday, December 22nd. Finally, Northland Securities reissued a buy rating and issued a $10.00 price objective on shares of Viewray in a report on Friday, November 17th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. Viewray presently has an average rating of Buy and an average price target of $11.20.
Viewray (NASDAQ:VRAY) traded down $0.52 during trading hours on Monday, reaching $9.60. 1,156,600 shares of the company’s stock were exchanged, compared to its average volume of 1,099,578. The company has a debt-to-equity ratio of -1.67, a current ratio of 1.59 and a quick ratio of 1.20. The firm has a market capitalization of $648.42, a PE ratio of -8.50 and a beta of 0.13. Viewray has a 52 week low of $3.01 and a 52 week high of $10.64.
Institutional investors and hedge funds have recently modified their holdings of the company. Nationwide Fund Advisors lifted its position in shares of Viewray by 843.2% during the second quarter. Nationwide Fund Advisors now owns 16,543 shares of the company’s stock worth $107,000 after purchasing an additional 14,789 shares in the last quarter. HighTower Advisors LLC lifted its position in shares of Viewray by 5.0% during the second quarter. HighTower Advisors LLC now owns 21,000 shares of the company’s stock worth $135,000 after purchasing an additional 1,000 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new stake in shares of Viewray during the second quarter worth about $159,000. Thompson Siegel & Walmsley LLC acquired a new stake in shares of Viewray during the third quarter worth about $164,000. Finally, White Pine Capital LLC acquired a new stake in shares of Viewray during the second quarter worth about $173,000. 50.02% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This article was first posted by BBNS and is the property of of BBNS. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://baseballnewssource.com/markets/viewray-vray-given-a-13-00-price-target-by-cantor-fitzgerald-analysts/1817756.html.
Viewray Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.